Showing posts with label Ganoderma lucidum. Show all posts
Showing posts with label Ganoderma lucidum. Show all posts

Wednesday, October 14, 2015

What research says about the Health Benefits of Ganoderma/Reishi/Lingzhi?

Ganoderma Lucidum/Reishi benefits us in the following ways: 

Reduces or normalises Blood Pressure; 
Offers Cardiovascular Benefits 

Ganoderma Lucidum has been shown in some studies to inhibit platelet aggregation and reduce blood pressure. 

In studies of people with hypertension, researchers found blood pressure was significantly reduced over two-weeks' time with reishi supplementation.

Platelet aggregation


Tao et. al. (1990) found that in vitro,  the reaction speed of platelet aggregation was significantly slowed down after application of Ganoderma extract in relation to its dosage. They continued their studies with 15 healthy volunteers and 33 patients with atherosclerotic diseases administering each person 3 grams a day for 2 weeks. This showed that Ganoderma reduced weight and length of the thrombi and reduced the aggregation events - statistically significantly. They concluded that their results suggested that the Chinese herbal medicine GL may be an effective inhibitory agent of platelet aggregation.



Gau et.al. (1990) investigated the  possible problems arising from the aggregation blocking properties in HIV-positive hemophiliacs. They found that Ganoderma, despite a high content of adenosine, which plays an important key role in antiplatelet effects, did not execute any increased risk. Platelet aggregation tests before and after administering of the extract showed no significant changes.

Su et.al. (2000) were able to show that besides  high adenosine levels,  Ganodermic acid S also contributes to the antiplatelet effects by influencing the biochemical pathways of platelet reaction. A normalization of platelet aggregation and thrombotic activities towards a physiological level contributes to a lower blood viscosity, which relieves the cardiovascular system of additional work load and improves therefore,  indirectly  the efficiency and O2 balance of the coronary system.   

Effects on serum cholesterol levels

Berger et.al. (2003)  from the Nestle Research Center, Lausanne , Switzerland, found that Ganoderma has the ability to lower not only total serum cholesterol, but also LDL, which is besides  VLDL,  the critical factor of cholesterol content. They conclude: “Innovative new cholesterol lowering foods and medicines containing Ganoderma lucidum are envisioned.”


A more recent publication from Hajjaj et.al. also from the Nestle Research Center in Switzerland, showed that triterpenoids are responsible for inhibiting lanosterol to be transformed into cholesterol. These findings are important in so far  since 60 – 70% of body cholesterol is synthesized and only 30 – 40% is added through our food intake. Controlled cholesterol intake and cholesterol synthesis inhibition seem to be the most promising and complementary measures for a regulated and normal serum level.

 Powerful Anti-oxidant


 Sun et.al. (2004)  reported that a Ganoderma lucidum peptide (GLP) is the major antioxidant component of Ganoderma Lucidum and could play so an important role in the inhibition of lipid peroxidation in biological systems through its antioxidant, metal chelating, and free radical scavenging activities.

Wachtel-Galor et.al. (2004) conducted  a double-blind, placebo-controlled, cross-over intervention study which investigated the effects of 4 weeks Lingzhi supplementation on a range of biomarkers for antioxidant status, Coronary Heart Disease risk, DNA damage, immune status, and inflammation, as well as markers of liver and renal toxicity with 18 healthy adults. No side effects have been reported, while the antioxidant capacity in urine and plasma increased significantly.







Other reports (Futrakul et.al., 2003) indicate  the anti-oxidant properties contribute to a better treatment of nephrosis.  Ganoderma seems to protect the cell membrane against lipid oxidation and ultimately against cell death.

Shieh et.al. (2001) observed  a liver and kidney protective mechanism due to Ganoderma’s prominent superoxide scavenging effect.

Lee et.al. (2001) assumed  a chemopreventive potential of Ganoderma, through a specific aminopolysaccharide fraction with a strong anti-oxidative performance found in this mushroom.

Immune-modulating Benefits &
Cancer treatment

Ganoderma Lucidum is commonly prescribed by practitioners for long-term immune system support. 

In studies involving patients with advanced tumors, the patients were given Ganoderma Lucidum for thirty days. Researchers found a marked immune-modulating effect as demonstrated by an increase in T lymphocytes and decreased CD8 counts. 

Patients also reported reduced side effects due to chemotherapy or radiation as well as post-operation recovery. 


Prostate enlargement

Fujita et.al. (2005) found a strong intervention of Ganoderma extracts on the metabolism of
testosterone into dihydrotestosterone through 5alpha-reductase inhibition. The biological activity of dihydrotestosterone is 2 times higher than that of testosterone and its receptor-binding capability is 5 times the capacity of testosterone. The authors concluded  that Ganoderma lucidum might be a useful ingredient for the treatment of benign prostatic hyperplasia (BPH).

Lung and Prostate cancer
Sliva D. et.al.(2003) described in a series of publications the possible use of Ganoderma in lung and prostate cancer, where it has clearly shown to inhibit the outspread and migration of tumor cells, which limits or even prevents metastasis of malignant cancer cells.


Asthma

Jiang et.al. (2004)  found out that Ganoderma prevents the growth of prostate cancer cells and induces cell death of malignant cells through a complex system of biochemical and molecular interactions. They concluded that Ganoderma seems to have potential therapeutic use for the prevention and treatment of cancer.
Liu et.al. (2006)  isolated two triterpenoids, ganoderic acids, which showed remarkable 5alphareductase inhibitory activities. 

Balances Blood Sugar 

Studies have shown Ganoderma Lucidum to have a blood sugar lowering effect. Much of this activity appears to be due to polysaccharides known as Ganoderans A, B, and C.   

There appears to be  three main mechanisms behind this hypoglycemic effect. This includes Ganoderma Lucidum's ability to elevate plasma insulin levels, to enhance peripheral tissue utilization of glucose, and to enhance liver metabolism of glucose.  

Regain Pancreatic function

The Medical Research Institute of Kinki University found in yearly experiments that Ganoderma has the same function as insulin. Accordingly, after taking Ganoderma, not only can insulin deficiency be supplemented, but it can make the pancreas regain its original function. In addition, it does not have any side effects like injections do.

Annular pancreas is an abnormal ring or collar of pancreatic tissue that encircles the duodenum (the...

Lowers blood sugar

Zhang et.al. (2003)  treated mice and found a subsequent decrease of insulin producing cells, while Ganoderma treated mice showed no decrease. Since free radicals are considered to play the damaging role, the Ganoderma effect is that of scavenging these free radicals and eliminating them before they are able to destroy the insulin producing units (Langerhans’ islets). 
In 2004,  the same group found that Ganoderma polysaccharides increased the Ca2+ influx into the pancreatic beta cells and induced,  hence a higher insulin release of these beta cells, which explains the blood sugar lowering effects of Ganoderma.

Renal/kidney disease

In experiments with patients suffering from renal disease,  Prof. Fumio Tsurudani of the Nagoya University Medical Institute, Japan, found that Ganoderma  could not only lower proteinuria and cholesterolemia, but also could  maintain proper renal function. 

Blood from the aorta reaches the kidneys so it can be filtered and cleaned. Among other functions...

Provides Anti-inflammatory Effects

Studies have shown that hot-water extracts of Ganoderma Lucidum have anti-inflammatory effects. 

One study found that 50 milligrams of Reishi powder had comparable effects to 5 milligrams of hydrocortisone.   

Protects the Liver

Ganoderma Lucidum has been  used for its hepatoprotective (liver protective) action. 


Human Anatomy: Antererior View of the Liver

A study of patients with hepatitis B and elevated liver enzymes (SGOT/SGPT) and bilirubin were given Reishi for three months. Significant reduction in SGOT and SGPT were noticed within one month. After three months, all values were within normal range.

Oxygenation

One of the unique uses of Ganoderma Lucidum is for altitude sickness. Reishi appears to reduce altitude sickness by oxygenating the blood. 

Insomnia/headache /Irritability

Tang et.al. (2005)  reported  a controlled study of   132 neurasthenia patients over a period of 8 weeks. The group with Ganoderma showed a significantly improved Global Clinical Impression, compared with the placebo group. 


The application of Ganoderma seemed to be responsible for decreasing signs of insomnia, headaches, and irritability.

300 x 11

(Also read the Pharmacological and clinical research on Ganoderma lucidum
(Lingzhi) in China- see  http://www.worldpharma2010.org/pp/FC16.2.1.pdf) 
References:

el-Mekkawy S, Meselhy MR, Nakamura N, et al. Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochem 1998;49:1651-7.

Gao Y, Zhou S, Jiang W, et al. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 2003;32:201-15.

Gau JP, Lin CK, Lee SS, et al. The lack of antiplatelet effect of crude extracts from ganoderma lucidum on HIV-positive hemophiliacs. Am J Chin Med 1990;18:175-9.

Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic neuralgia. Am J Chin Med 1998;26:375-81.

Hikino H, Ishiyama M, Suzuki Y, et al. Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies. Planta Med 1989;55:423-8.

Kim DH, Shim SB, Kim NJ, et al. Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol Pharm Bull 1999;22:162-4.

Kim HS, Kacew S, Lee BM. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis 1999;20:1637-40.

Kim RS, Kim HW, Kim BK. Suppressive effects of Ganoderma lucidum on proliferation of peripheral blood mononuclear cells. Mol Cells 1997;7:52-7.

Komoda Y, Shimizu M, Sonoda Y, et al. Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull (Tokyo) 1989;37:531-3.

Kwok Y, Ng KFJ, Li, CCF, et al. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 2005;101:423-6.

Lee SY, Rhee HM. Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull (Tokyo) 1990;38:1359-64.

Min BS, Nakamura N, Miyashiro H, et al. Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Chem Pharm Bull (Tokyo) 1998;46:1607-12.

Singh AB, Gupta SK, Pereira BM, et al. Sensitization to Ganoderma lucidum in patients with respiratory allergy in India. Clin Exp Allergy 1995;25:440-7.

Sun J, He H, Xie BJ. Novel antioxidant peptides from fermented mushroom Ganoderma lucidum. J Agric Food Chem 2004;52:6646-52.

Tao J, Feng KY. Experimental and clinical studies on inhibitory effect of ganoderma lucidum on platelet aggregation. J Tongji Med Univ 1990;10:240-3.

van der Hem LG, van der Vliet JA, Bocken CF, et al. Ling Zhi-8: studies of a new immunomodulating agent. Transplantation 1995;60:438-43.

Wang SY, Hsu ML, Hsu HC, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 1997;70:699-705.

Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 1999;19:65-96.

Yoon SY, Eo SK, Kim YS, et al. Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics. Arch Pharm Res 1994;17:438-42.

Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 2005;53:11-7

Other sources you can refer to: 

8 Weeks To Optimum Health By Andrew Weil MD, p. 15

Viral Immunity by J.E, p. 292

Miracle Medicine Herbs by Richard M. Lucas, p. 9

Off The Shelf Natural Health How To Use Herbs And Nutrients To Stay Well By Mark Mayell, p. 88

Prescription For Dietary Wellness by Phyllis A. Balch, p. 167

The Herbal Drugstore by Linda B. White MD, p. 327

Thursday, July 16, 2015

News of Ganoderma



The article is written by 'The Edge' (It is a weekly hot selling newspaper in Malaysia) after having an interview session with DXN CEO Dr.Lim Siow Jin.
Corporate News: DXN prospers on mushrooms By Isa Ismail

When Dr Lim Siow Jin introduced his locally produced Ganoderma extracts and health care products to pharmacies and herb shops in his home state of Kedah, he found that there were few takers.

Ganoderma is a species of mushroom that is more popularly known among the Chinese community as Lingzhi and is believed to have properties that can cure a host of illnesses from coronary diseases to ulcers and depression.
Lim has found a way to mass-produce the mushroom and its end-products locally with local content.

"But consumers just couldn't believe that Ganoderma could be produced in a place like Kedah," exclaims Lim. "When you talk about Ganoderma, people think that it comes from nowhere else but Japan, China and Taiwan."
Numerous rejections from sceptical consumers inevitably led Lim to come up with the idea of multi-level marketing (MLM). This set the direction for Lim and the establishment of his company DXN Holdings Bhd, as it got off the ground in the early 1990s.

"Compared with reading the labels on our products, MLM is more convincing because through word of mouth we can better explain how good our products are," Lim says in an interview with The Edge. "Ganoderma produced in Malaysia is as good as that produced in East Asia."

Evidently, DXN's produ
cts have found acceptance in the local market, enabling the company to be listed soon on the Kuala Lumpur Stock Exchange.
But still there were challenges.

How was DXN going to compete with the brand image of Ganoderma products from Japan and China? Lim says the answer came in the form of recognition for cleanliness and safety.

"One of the ways was to set up a good manufacturing practice (GMP)-certified factory," Lim explains. "This is a factory with a modern set-up that meets the standards set by authorities like the Drug Control Authority of Malaysia."

After DXN had established its processing facilities, the next step was the marketing strategy. Lim started small, recruiting members from Kedah and elsewhere in the country. But by 1995, he says, business boomed. DXN came up with many different products containing Ganoderma besides offering it in tablet form. Among these products are DXN's 3-in-1 Lingzhi coffee, toothpaste and cosmetics.

"We may not be the only Ganoderma mushroom producer in the country but we are certainly the largest in terms of capacity," Lim claims. "We are a complete company in the sense that we do the cultivation, processing and marketing of Ganoderma. We not only sell our products locally but also sell to the whole world. We already have branches in 11 countries."

Lim began to dabble in cultivating Ganoderma as a hobby in the early 1980s. His father was a herbalist and the two of them had a keen interest in this mushroom. They, too, thought that Ganoderma, like Ginseng, could only be found in China and Japan.

"But in the 1980s, we found Ganoderma in our own jungles," recalls Lim. "It was great news to us as Ganoderma is a better herb than Ginseng. So in 1984, we went into the jungle to get the mushroom. We used tissue culture to acclimatise the mushroom for commercial cultivation. We did a lot of toxicity tests to ascertain that what we had found was really Ganoderma."

By the late 1980s, Lim was already producing Ganoderma on a small scale. His Ganoderma extracts were introduced to friends and family members who found that the mushhroom was very effective.

"[But] it was not easy to cultivate Ganoderma," explains Lim. "First you need to get the seeds, or more accurately called 'spawn', and then we had to work out what materials to use to grow the mushroom.

"Books will tell you that you need cotton wood sawdust, wheat bran. But in Kedah, we only have rubber wood and rice and so we used rubber wood sawdust and rice bran. The only foreign materials that we needed were barley and corn. We only required a small amount but they are easily available in the market."
As almost all of DXN's raw materials were sourced locally, Lim's products were selling at a third of the price of imported Ganoderma. And this helped DXN gain a foothold in the market.

DXN registered net profits in the region of RM15 million for the financial years ending February 2002 and 2003. Turnover during these periods hovered around RM120 million.

Sales in Malaysia only contributed about 20 per cent of the company's total turnover. Its largest foreign market is the Philippines, which contributes about 43 per cent. DXN's most popular product is the 3-in-1 Lingzhi coffee, accounting for 74 per cent of the company's total sales.

"Our coffee was the first product that actually ran out of stock," says Lim. "Our members in the Philippines had sold all their Lingzhi coffee and we had to rush our production to meet the demand."

Today, the company has up to two million members under its MLM scheme.
Its products have won over not only the Chinese community and foreigners but also non-Chinese Malaysians.

"A good-quality product will eventually bring in the customers," Lim says.

Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota

Ganoderma weight loss

Obesity is associated with low-grade chronic inflammation and intestinal dysbiosis. Ganoderma lucidum is a medicinal mushroom used in traditional Chinese medicine with putative anti-diabetic effects. Here, we show that a water extract of Ganoderma lucidum mycelium (WEGL) reduces body weight, inflammation and insulin resistance in mice fed a high-fat diet (HFD). Our data indicate that WEGL not only reverses HFD-induced gut dysbiosis-as indicated by the decreased Firmicutes-to-Bacteroidetes ratios and endotoxin-bearing Proteobacteria levels-but also maintains intestinal barrier integrity and reduces metabolic endotoxemia. The anti-obesity and microbiota-modulating effects are transmissible via horizontal faeces transfer from WEGL-treated mice to HFD-fed mice. We further show that high molecular weight polysaccharides (>300 kDa) isolated from the WEGL extract produce similar anti-obesity and microbiota-modulating effects. Our results indicate that Ganoderma lucidum and its high molecular weight polysaccharides may be used as prebiotic agents to prevent gut dysbiosis and obesity-related metabolic disorders in obese individuals. 

Traditional Chinese Medicine has a long history in Asian countries dating back several thousands of years. One class of traditional remedies commonly in use consists of medicinal mushrooms such as Ophiocordyceps sinensis, Antrodia cinnamomea and Agaricus blazei Murrill, which contain a wide range of immuno-modulatory and bioactive compounds. One of the most intriguing medicinal mushrooms is the Basidiomycete fungus Ganoderma lucidum, which has been used for centuries to promote health and longevity. Previous studies have shown that triterpenes and polysaccharides isolated from Ganoderma lucidum inhibit adipocyte differentiation and produce hypoglycaemia effects in diabetic mice. In addition, proteoglycans isolated from Ganoderma lucidum fruiting bodies induce antidiabetic, antihyperlipidemic and antioxidant activities. However, it remained unknown whether Ganoderma lucidum produces any effect on body weight and obesity-related disorders.

Obesity is defined as a disease condition associated with numerous health problems and a reduced life expectancy. Growing evidence indicates that obesity is closely linked with chronic, low-grade inflammation, which can lead to insulin resistance, type 2 diabetes, fatty liver disease, cardiovascular disease, obstructive sleep apnoea and cancer. The high prevalence of obesity is currently a major threat to public health, with ~500 million obese people and 1.4 billion overweight individuals worldwide. Prevention of obesity thus represents a major challenge for modern societies.


A recent study indicates that changes in the composition of the gut microbiota are associated with the development of obesity and its associated metabolic disorders. The gut microbiota comprises trillions of bacteria that contribute to nutrient acquisition and energy regulation. An increased ratio of the major phyla Firmicutes/Bacteroidetes and changes in several bacterial species can promote the development of obesity in both dietary and genetic models of obesity in mice. Other studies in obese animals suggest that obesity-induced gut dysbiosis caused by either environmental or genetic factors impairs intestinal integrity. This process leads to the release of the endotoxin lipopolysaccaride (LPS) from intestinal Gram-negative bacteria into the bloodstream, in turn, leading to metabolic inflammation and insulin resistance in obese mice due to stimulation of Toll-like receptor 4 (TLR4)-mediated inflammation. Moreover, chronic injection of LPS in mice leads to mild obesity and insulin resistance, highlighting a possible role for microbiota-derived LPS in obesity-induced inflammation.


Ganoderma WEGLA number of treatments, including antibiotics and prebiotics, are being evaluated for the management of obesity and its related metabolic disorders. For example, antibiotic treatment alters the gut microbiota, reduces blood endotoxemia and improves glucose tolerance in mice lacking the leptin gene (ob/ob mice) or in mice fed with a HFD. In addition, prebiotics are non-digestible, fermentable carbohydrates and fibres, which reduce body weight and exert anti-inflammatory effects mainly by enhancing the growth of specific beneficial bacteria found in the gut. Prebiotics not only alter the intestinal microbiota but also improve intestinal tight junction integrity and decrease blood endotoxemia caused by LPS. Prebiotics may, therefore, protect animals against obesity-induced inflammation.

In the present study, we examined whether a water extract of Ganoderma lucidum mycelium (WEGL) can decrease obesity in HFD-fed mice. Our results indicate that WEGL reduces obesity and inflammation in the treated mice. These effects are transmissible to HFD-fed mice through horizontal faeces transplantation, indicating that the effects of WEGL involve the gut microbiota. Characterization of WEGL showed that polysaccharides of molecular weight >300 kDa exerted similar ameliorative effects as WEGL. These results implied that the high molecular weight polysaccharides may be the active components of WEGL. Our data thus demonstrate that WEGL represents a potential prebiotic agent that may be used for the treatment of obesity and its complications.